Fundraising FoxTarsa Therapeutics
Philadelphia, US · Founded 2009 · Delaware corporation · 4 known investors
Find your way into Tarsa Therapeutics
Sign up to see every warm intro you have to Tarsa Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tarsa Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable. The drug, tested in the Phase 3 ORACAL trial, is a pharmaceutical treatment whose rights have been acquired by R-Pharm JSC.
Founders & leadership
Board
RK
Richard KollenderBoard director
ME
Martin EdwardsBoard director
EB
DF
Derek FergusonBoard director
JT
James TananbaumBoard director
MR
Matthew RiekeBoard director
AP
Ashleigh PalmerBoard director
Investors · 4
Foresite CapitalreportedWest Hollywood
How we know: board seat on SEC Form D · funding news · biospace.com · Not right? Tell us
MVM Life Science PartnersreportedLondon · $20M – $100Mvia Eric Bednarski · board
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Oxford Finance LLCreportedAlexandria
How we know: funding news · Not right? Tell us
Quaker BioVenturesreported
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$19.2M disclosed across 5 rounds · 2012–2017
▶$549.9KraisedJul 2017 · 3 investors · BiotechnologyRule 506(b)
▶$549.9KraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric BednarskiDirector
- Richard KollenderDirector
- Martin EdwardsDirector
- Gregory LumpkinExecutive Officer
- David BrandExecutive Officer, Director
- Richard LevyDirector
- Offering amount
- $1M
- Amount sold
- $549.9K
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJan 2017 · 5 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJan 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard KollenderDirector
- Martin EdwardsDirector
- Eric BednarskiDirector
- James TananbaumDirector
- Lewis GeffenExecutive Officer
- Gregory LumpkinExecutive Officer
- Richard LevyDirector
- David BrandExecutive Officer, Director
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedJul 2016 · 7 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJul 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lewis GeffenExecutive Officer
- Eric BednarskiDirector
- Gregory LumpkinExecutive Officer
- Martin EdwardsDirector
- Richard KollenderDirector
- James TananbaumDirector
- Derek FergusonDirector
- David BrandExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedFeb 2016 · 7 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BrandExecutive Officer, Director
- Richard KollenderDirector
- Martin EdwardsDirector
- Eric BednarskiDirector
- Gregory LumpkinExecutive Officer
- Derek FergusonDirector
- Lewis GeffenExecutive Officer
- James TananbaumDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.8MraisedMar 2012 · 5 investors · BiotechnologyRule 506(b)
▶$13.8MraisedMar 2012 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric BednarskiDirector
- Lewis GeffenExecutive Officer
- Ashleigh PalmerDirector
- Gregory LumpkinExecutive Officer
- David BrandExecutive Officer, Director
- James TananbaumDirector
- Martin EdwardsDirector
- Matthew RiekeDirector
- Offering amount
- $28M
- Amount sold
- $13.8M
- First sale
- Mar 2012
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Tarsa Therapeutics do?
- Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable. The drug, tested in the Phase 3 ORACAL trial, is a pharmaceutical treatment whose rights have been acquired by R-Pharm JSC.
- Who are Tarsa Therapeutics's investors?
- Tarsa Therapeutics's investors include Foresite Capital, MVM Life Science Partners, Oxford Finance LLC, Quaker BioVentures.
- How much funding has Tarsa Therapeutics raised?
- Tarsa Therapeutics has disclosed $19.2M raised across 5 rounds.
- Where is Tarsa Therapeutics headquartered?
- Tarsa Therapeutics is headquartered in Philadelphia, US.